Genetic newborn screening could help detect early-onset cancer risk, according to a new study published in Nature Communications. The research analyzed archived dried blood spots from 1,948 Michigan children who later developed solid tumors or central nervous system cancers by age eight. Using an 11-gene panel, researchers identified pathogenic or likely pathogenic germline variants in 132 children, or 6.8% of the cohort. The findings suggest that screening for specific cancer predisposition genes might be feasible within the existing framework of newborn screening programs.
Genomic newborn screening provides a platform for identifying high-risk children to institute vetted surveillance protocols. The goal of this research is not to predict every childhood cancer, but to identify infants at risk for specific syndromes where surveillance protocols already exist. The study focused on 11 genes, including RB1, RET, TP53, WT1, and SMARCB1. Richard B. Parad, MD, MPH, co-senior author of the study, noted that these 11 genes offer a practical entry point for expanding current screening frameworks.
Retinoblastoma provides the clearest evidence of potential benefit. Germline RB1 variants were found in 69 children, 68 of whom later developed the disease. Among children with known bilateral retinoblastoma, 80% carried a detectable RB1 variant at birth. Infants with these variants can undergo regular ophthalmologic exams, allowing tumors to be detected when they are smaller and more amenable to local therapies. In the study, children with germline RB1 variants were diagnosed at a median of nine months, compared to 23 months for those without detected variants. Lisa Diller, MD, vice chair of Pediatric Oncology at Dana-Farber, said finding an early tumor or pre-tumor saves that child from a more difficult-to-treat and sometimes fatal diagnosis.
The links between other genes and tumors were similarly specific. All six children who developed medullary thyroid carcinoma carried germline RET variants. WT1 variants were detected in seven infants who later developed renal tumors, and TP53 variants were found in 24 children who developed cancers including sarcomas, CNS tumors, and adrenal malignancies.
The authors believe genomic newborn screening could shift some pediatric cancers from symptomatic diagnosis toward genetically guided surveillance. However, the study has limitations that must be addressed before widespread implementation. The analysis was retrospective and focused only on children who later developed cancer, rather than a full prospective newborn population followed over time. The study also used a limited 11-gene panel and relied on archived samples from one U.S. state.
Broad implementation would require prospective evidence, ancestry-diverse validation, cost-effectiveness analysis, and careful management of the psychosocial burden. The findings sharpen the debate on whether selected cancer-risk genes belong in the conversation for genomic newborn screening. The study is significant because it demonstrates that targeting the weaknesses found in pancreatic cancer cells might be possible through early detection. While the study highlights a potential pathway for early intervention, the logistical and ethical hurdles remain significant.
Leave a Reply